An interventional study of BONGO NASAL EPAP in Obstructive Sleep Apnea, sponsored by InnoMed Healthscience Inc.. Terminated at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2017-08-21.
Sponsored by InnoMed Healthscience Inc. · Not applicable, Interventional, and Treatment
Single center clinical study for the BONGO NASAL EPAP device in the treatment of obstructive sleep apnea for the purpose of obtaining safety and efficacy data
1,422 studies on the registry are indexed under Apnea; 159 are open to participants now.
This study's enrollment of 9 is below the median of 50 across 965 interventional studies indexed under Apnea.
Browse Apnea studies →InnoMed Healthscience Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The BONGO NASAL EPAP device consists of two nasal inserts (a connected pair), each containing an actuated valve, with a patient attachment mechanism. The device works by providing an inhalation port that offers minimal inhale resistance during inhalation, but is closed by the actuated valve so that exhalation occurs against a fixed orifice. This mechanism provides increased EPAP upon exhalation.
Apnea Hypopnea Index
Time frame: 2 weeks
This study is terminated, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
InnoMed Healthscience Inc.